Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
20
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Chavez Margarita | Director | 3 | $0 | $0 | 2026-06-25 |
| Hirth Peter | Director | 8 | $0 | $0 | 2026-06-25 |
| Nuechterlein Carole | Director, 10% Owner | 16 | $6.55M | $0 | 2026-06-25 |
| Martell Bridget A | Director | 8 | $0 | $0 | 2026-06-25 |
| Preston Heather | Director | 3 | $0 | $0 | 2026-06-25 |
| Scopa James Paul | Director | 10 | $0 | $0 | 2026-06-25 |
| Aneja Nikhil | Principal Accounting Officer | 1 | $0 | $0 | 2026-03-09 |
| Symons Julian A. | See Remarks | 23 | $0 | $0 | 2026-03-09 |
| Calhoun Lesley Ann | See Remarks | 17 | $0 | $0 | 2026-03-09 |
| BLATT LAWRENCE | President and CEO | 39 | $0 | $0 | 2026-03-09 |
| Achneck Hardean | Chief Medical Officer | 1 | $0 | $0 | 2024-10-08 |
| McClure Matthew W. | Chief Medical Officer | 10 | $0 | $0 | 2024-03-01 |
| Nielsen Jack | Director | 5 | $0 | $0 | 2024-02-28 |
| Quan Lucinda Y. | See Remarks | 12 | $0 | $0 | 2023-09-08 |
| Beigelman Leonid | President | 23 | $0 | $0 | 2023-03-15 |
| Woiwode Thomas | Director | 25 | $3.00M | $0 | 2022-06-23 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | 4 | $0 | $0 | 2020-10-20 |
| Versant Venture Capital VI, L.P. | 10% Owner | 11 | $3.00M | $0 | 2020-10-20 |
| Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | 14 | $8.25M | $0 | 2020-10-20 |
| Novo Holdings A/S | 10% Owner | 5 | $3.00M | $0 | 2020-10-20 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Hirth Peter | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Chavez Margarita | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Preston Heather | Director | A Award deriv | 2026-06-25 | 2026-06-29 | 5,860 | — | $0 | 5,860 | SEC↗ |
| BLATT LAWRENCE | President and CEO | A Award deriv | 2026-03-09 | 2026-03-11 | 105,840 | — | $0 | 105,840 | SEC↗ |
| Calhoun Lesley Ann | See Remarks | A Award deriv | 2026-03-09 | 2026-03-11 | 37,485 | — | $0 | 37,485 | SEC↗ |
| Aneja Nikhil | Principal Accounting Officer | A Award deriv | 2026-03-09 | 2026-03-11 | 9,450 | — | $0 | 9,450 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2026-03-09 | 2026-03-11 | 23,310 | — | $0 | 23,310 | SEC↗ |
| Calhoun Lesley Ann | See Remarks | A Award deriv | 2025-07-16 | 2025-07-18 | 40,185 | — | $0 | 40,185 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2025-07-16 | 2025-07-18 | 16,000 | — | $0 | 16,000 | SEC↗ |
| BLATT LAWRENCE | President and CEO | A Award deriv | 2025-07-16 | 2025-07-18 | 179,800 | — | $0 | 179,800 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Chavez Margarita | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Preston Heather | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2025-06-25 | 2025-06-26 | 5,860 | — | $0 | 5,860 | SEC↗ |
| Calhoun Lesley Ann | See Remarks | A Award deriv | 2025-02-28 | 2025-03-04 | 47,271 | — | $0 | 47,271 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2025-02-28 | 2025-03-04 | 21,693 | — | $0 | 21,693 | SEC↗ |
| BLATT LAWRENCE | President and CEO | A Award deriv | 2025-02-28 | 2025-03-04 | 140,103 | — | $0 | 140,103 | SEC↗ |
| Achneck Hardean | Chief Medical Officer | A Award deriv | 2024-10-08 | 2024-10-10 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2024-09-04 | 2024-09-06 | 10,880 | — | $0 | 10,880 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2024-09-04 | 2024-09-06 | 33,920 | — | $0 | 33,920 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2024-09-04 | 2024-09-06 | 10,880 | — | $0 | 10,880 | SEC↗ |
| Preston Heather | Director | A Award deriv | 2024-08-07 | 2024-08-09 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Chavez Margarita | Director | A Award deriv | 2024-08-07 | 2024-08-09 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2024-06-27 | 2024-06-28 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2024-06-27 | 2024-06-28 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2024-06-27 | 2024-06-28 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2024-06-27 | 2024-06-28 | 60,000 | — | $0 | 60,000 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2024-03-01 | 2024-03-04 | 965,435 | — | $0 | 965,435 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2024-03-01 | 2024-03-04 | 72,000 | — | $0 | 72,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2024-03-01 | 2024-03-04 | 308,940 | — | $0 | 308,940 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2024-03-01 | 2024-03-04 | 72,000 | — | $0 | 72,000 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2024-02-28 | 2024-02-28 | 8,823 | — | $0 | 8,823 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2024-02-28 | 2024-02-28 | 4,411 | — | $0 | 4,411 | SEC↗ |
| Nielsen Jack | Director | A Award deriv | 2024-02-28 | 2024-02-28 | 4,411 | — | $0 | 4,411 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2024-02-28 | 2024-02-28 | 74,998 | — | $0 | 74,998 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2024-02-28 | 2024-02-28 | 58,822 | — | $0 | 58,822 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2024-02-28 | 2024-02-28 | 18,750 | — | $0 | 18,750 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 57,749 | — | $0 | 57,749 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 230,999 | — | $0 | 230,999 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 132,352 | — | $0 | 132,352 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2024-02-28 | 2024-02-28 | 18,750 | — | $0 | 18,750 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2024-02-28 | 2024-02-28 | 74,998 | — | $0 | 74,998 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2024-02-28 | 2024-02-28 | 51,833 | — | $0 | 51,833 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 75,183 | — | $0 | 75,183 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 16,428 | — | $0 | 16,428 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2024-02-28 | 2024-02-28 | 65,713 | — | $0 | 65,713 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2024-02-28 | 2024-02-28 | 8,823 | — | $0 | 8,823 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2024-02-28 | 2024-02-28 | 4,411 | — | $0 | 4,411 | SEC↗ |
| Martell Bridget A | Director | D To issuer deriv | 2024-02-27 | 2024-02-28 | 30,000 | — | $0 | 0 | SEC↗ |
| Nuechterlein Carole | Director | D To issuer deriv | 2024-02-27 | 2024-02-28 | 15,000 | — | $0 | 0 | SEC↗ |
| Nielsen Jack | Director | D To issuer deriv | 2024-02-27 | 2024-02-28 | 15,000 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | D To issuer deriv | 2024-02-27 | 2024-02-28 | 26,250 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | D To issuer deriv | 2024-02-27 | 2024-02-28 | 200,000 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | D To issuer deriv | 2024-02-27 | 2024-02-28 | 105,000 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 80,850 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 450,000 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 323,400 | — | $0 | 0 | SEC↗ |
| Calhoun Lesley Ann | Other | D To issuer deriv | 2024-02-27 | 2024-02-28 | 26,250 | — | $0 | 0 | SEC↗ |
| Calhoun Lesley Ann | Other | D To issuer deriv | 2024-02-27 | 2024-02-28 | 105,000 | — | $0 | 0 | SEC↗ |
| Calhoun Lesley Ann | Other | D To issuer deriv | 2024-02-27 | 2024-02-28 | 176,237 | — | $0 | 0 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 92,000 | — | $0 | 0 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 23,000 | — | $0 | 0 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | D To issuer deriv | 2024-02-27 | 2024-02-28 | 255,626 | — | $0 | 0 | SEC↗ |
| Scopa James Paul | Director | D To issuer deriv | 2024-02-27 | 2024-02-28 | 30,000 | — | $0 | 0 | SEC↗ |
| Hirth Peter | Director | D To issuer deriv | 2024-02-27 | 2024-02-28 | 15,000 | — | $0 | 0 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2023-10-25 | 2023-10-27 | 91,541 | $0.13 | $11.9K | 91,541 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2023-10-25 | 2023-10-27 | 305,138 | $0.13 | $39.7K | 305,138 | SEC↗ |
| Nuechterlein Carole | Director, 10% Owner | P Buy deriv | 2023-10-25 | 2023-10-27 | 3,966,800 | $0.13 | $515.7K | 3,966,800 | SEC↗ |
| Scopa James Paul | Director | A Award | 2023-10-25 | 2023-10-27 | 183,083 | $0.76 | $139.1K | 183,083 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award | 2023-10-25 | 2023-10-27 | 610,277 | $0.76 | $463.8K | 1,847,575 | SEC↗ |
| Nuechterlein Carole | Director, 10% Owner | P Buy | 2023-10-25 | 2023-10-27 | 7,933,601 | $0.76 | $6.03M | 11,025,941 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2023-09-08 | 2023-09-12 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2023-09-08 | 2023-09-12 | 48,000 | — | $0 | 48,000 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2023-09-08 | 2023-09-12 | 48,000 | — | $0 | 48,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2023-09-08 | 2023-09-12 | 48,000 | — | $0 | 48,000 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2023-09-08 | 2023-09-12 | 48,000 | — | $0 | 48,000 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2023-07-20 | 2023-07-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2023-07-20 | 2023-07-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2023-07-20 | 2023-07-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Nielsen Jack | Director | A Award deriv | 2023-07-20 | 2023-07-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2023-07-20 | 2023-07-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2023-03-15 | 2023-03-17 | 242,500 | — | $0 | 242,500 | SEC↗ |
| Beigelman Leonid | President | A Award deriv | 2023-03-15 | 2023-03-17 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2023-03-15 | 2023-03-17 | 78,750 | — | $0 | 78,750 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2023-03-15 | 2023-03-17 | 78,750 | — | $0 | 78,750 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2023-03-15 | 2023-03-17 | 78,750 | — | $0 | 78,750 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2023-03-15 | 2023-03-17 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2022-07-07 | 2022-07-11 | 50,000 | — | $0 | 50,000 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2022-07-07 | 2022-07-11 | 161,700 | — | $0 | 161,700 | SEC↗ |
| Beigelman Leonid | President | A Award deriv | 2022-07-07 | 2022-07-11 | 113,000 | — | $0 | 113,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2022-07-07 | 2022-07-11 | 52,500 | — | $0 | 52,500 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2022-07-07 | 2022-07-11 | 52,500 | — | $0 | 52,500 | SEC↗ |
| McClure Matthew W. | Chief Medical Officer | A Award deriv | 2022-07-07 | 2022-07-11 | 46,000 | — | $0 | 46,000 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Nielsen Jack | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Woiwode Thomas | Director | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Beigelman Leonid | President | A Award deriv | 2022-02-04 | 2022-02-08 | 226,800 | — | $0 | 226,800 | SEC↗ |
| Beigelman Leonid | President | A Award deriv | 2022-02-04 | 2022-02-08 | 56,700 | — | $0 | 56,700 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2022-02-04 | 2022-02-08 | 26,250 | — | $0 | 26,250 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2022-02-04 | 2022-02-08 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2022-02-04 | 2022-02-08 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2022-02-04 | 2022-02-08 | 26,250 | — | $0 | 26,250 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2022-02-04 | 2022-02-08 | 80,850 | — | $0 | 80,850 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2022-02-04 | 2022-02-08 | 323,400 | — | $0 | 323,400 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2022-02-04 | 2022-02-08 | 26,250 | — | $0 | 26,250 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2022-02-04 | 2022-02-08 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2021-11-16 | 2021-11-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Nuechterlein Carole | Director | A Award deriv | 2021-06-17 | 2021-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Hirth Peter | Director | A Award deriv | 2021-06-17 | 2021-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Woiwode Thomas | Director | A Award deriv | 2021-06-17 | 2021-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Nielsen Jack | Director | A Award deriv | 2021-06-17 | 2021-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 8,383 | — | $0 | 8,383 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 9,719 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 9,719 | — | $0 | 9,719 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 2,226 | — | $0 | 4,452 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 8,383 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-06-11 | 2021-06-15 | 485,979 | — | $0 | 1,457,937 | SEC↗ |
| Scopa James Paul | Director | A Award deriv | 2021-04-26 | 2021-04-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 485,979 | — | $0 | 1,943,916 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 9,720 | — | $0 | 9,720 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 9,720 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 8,385 | — | $0 | 8,385 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 8,385 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | J Other | 2021-04-26 | 2021-04-28 | 2,226 | — | $0 | 2,226 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | A Award deriv | 2020-12-01 | 2020-12-03 | 450,000 | — | $0 | 450,000 | SEC↗ |
| Beigelman Leonid | President | A Award deriv | 2020-12-01 | 2020-12-03 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Quan Lucinda Y. | See Remarks | A Award deriv | 2020-12-01 | 2020-12-03 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Calhoun Lesley Ann | Other | A Award deriv | 2020-12-01 | 2020-12-03 | 176,237 | — | $0 | 176,237 | SEC↗ |
| Symons Julian A. | See Remarks | A Award deriv | 2020-12-01 | 2020-12-03 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,437 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 21,724 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 3,359 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 3,359 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 50,781 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 13,559 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 13,559 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 163,842 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,437 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 122,601 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 41,016 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 50,712 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 21,695 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 0 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 0 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 283,550 | — | $0 | 0 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 0 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 662,799 | — | $0 | 0 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 6,835 | — | $0 | 0 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 726 | — | $0 | 0 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,697 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 0 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 0 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 0 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 0 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 0 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 0 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 1,885,611 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 260,380 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 523,726 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 224,054 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 30,939 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-20 | 72,320 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 0 | SEC↗ |
| Woiwode Thomas | Director | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 0 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-22 | 1,335,048 | — | $0 | 0 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-22 | 571,143 | — | $0 | 0 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-22 | 1,609,493 | — | $0 | 0 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-22 | 241,219 | — | $0 | 0 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion deriv | 2020-10-20 | 2020-10-22 | 563,851 | — | $0 | 0 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 1,437 | — | $0 | 18,355 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 21,724 | — | $0 | 236,347 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 1,437 | — | $0 | 18,355 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 3,359 | — | $0 | 16,918 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 3,359 | — | $0 | 16,918 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 50,781 | — | $0 | 214,623 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 13,559 | — | $0 | 13,559 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 13,559 | — | $0 | 13,559 | SEC↗ |
| Beigelman Leonid | President | C Conversion | 2020-10-20 | 2020-10-20 | 163,842 | — | $0 | 163,842 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 41,016 | — | $0 | 41,016 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 50,712 | — | $0 | 91,728 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 13,671 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 13,671 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 122,601 | — | $0 | 122,601 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 17,065 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 18,517 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 17,065 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 21,695 | — | $0 | 113,423 | SEC↗ |
| BLATT LAWRENCE | Chief Executive Officer | C Conversion | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 18,517 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion | 2020-10-20 | 2020-10-20 | 662,799 | — | $0 | 2,808,790 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion | 2020-10-20 | 2020-10-20 | 283,550 | — | $0 | 3,092,340 | SEC↗ |
| Nuechterlein Carole | Director | C Conversion | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 2,145,991 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 1,697 | — | $0 | 8,532 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 726 | — | $0 | 9,258 | SEC↗ |
| Quan Lucinda Y. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 6,835 | — | $0 | 6,835 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 1,452 | — | $0 | 394,064 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 3,394 | — | $0 | 392,612 | SEC↗ |
| Symons Julian A. | See Remarks | C Conversion | 2020-10-20 | 2020-10-20 | 13,671 | — | $0 | 389,218 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 2,344,830 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 463,959 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 2,429,895 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 662,444 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 2,145,991 | SEC↗ |
| Versant Venture Capital VI, L. | 10% Owner | P Buy | 2020-10-20 | 2020-10-20 | 200,000 | $15.00 | $3.00M | 862,444 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 260,380 | — | $0 | 260,380 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 1,885,611 | — | $0 | 1,885,611 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | P Buy | 2020-10-20 | 2020-10-20 | 483,267 | $15.00 | $7.25M | 3,116,658 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 30,939 | — | $0 | 363,639 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 72,320 | — | $0 | 332,700 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | P Buy | 2020-10-20 | 2020-10-20 | 66,733 | $15.00 | $1.00M | 430,372 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 224,054 | — | $0 | 2,633,391 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2020-10-20 | 2020-10-20 | 523,726 | — | $0 | 2,409,337 | SEC↗ |
| Woiwode Thomas | Director | C Conversion | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 662,444 | SEC↗ |
| Woiwode Thomas | Director | P Buy | 2020-10-20 | 2020-10-20 | 200,000 | $15.00 | $3.00M | 862,444 | SEC↗ |
| Woiwode Thomas | Director | C Conversion | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 2,429,895 | SEC↗ |
| Woiwode Thomas | Director | C Conversion | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 2,145,991 | SEC↗ |
| Woiwode Thomas | Director | C Conversion | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 2,344,830 | SEC↗ |
| Woiwode Thomas | Director | C Conversion | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 463,959 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion | 2020-10-20 | 2020-10-22 | 1,335,048 | — | $0 | 1,335,048 | SEC↗ |
| Wellington Biomedical Innovati | 10% Owner | C Conversion | 2020-10-20 | 2020-10-22 | 571,143 | — | $0 | 1,906,191 | SEC↗ |
| Novo Holdings A/S | 10% Owner | P Buy | 2020-10-20 | 2020-10-22 | 200,000 | $15.00 | $3.00M | 2,614,563 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion | 2020-10-20 | 2020-10-22 | 2,414,563 | — | $0 | 2,414,563 | SEC↗ |